Last €0.31 EUR
Change Today +0.018 / 6.12%
Volume 0.0
LYF On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 2:08 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Open
€0.31
Previous Close
€0.29
Day High
€0.31
Day Low
€0.31
52 Week High
01/22/14 - €0.44
52 Week Low
09/17/14 - €0.26
Market Cap
131.7M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
422.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EKF DIAGNOSTICS HOLDINGS PLC (LYF)

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc is engaged in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and HbA1c. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians, as well as molecular diagnostic test kits, which are focused on applications within oncological research. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

330 Employees
Last Reported Date: 02/26/14
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 297.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Financial Officer, Secretary and Execut...
Total Annual Compensation: 19.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 214.0K GBP
Compensation as of Fiscal Year 2013.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Enters into Two Year Research Collaboration with Massachusetts General Hospital to Develop PointMan Assays to Effectively Detect Treatable Cancer Mutations in Blood Samples

EKF Diagnostics Holdings plc announced that it has entered into two year research collaboration with Massachusetts General Hospital to develop PointMan assays that can effectively detect treatable cancer mutations in blood samples. The collaboration agreement has been signed following a detailed evaluation of PointMan DNA enrichment technology by MGH and will cover a two year long project focusing on lung, breast and skin cancer. MGH will use PointMan DNA enrichment technology for the detection of genetic variation in circulating tumour cells (CTCs) isolated from a patient's blood using MGH's CTC-Chip instrument. CTCs are shed by primary tumors allowing the cancer to metastasise. CTCs are extremely rare in whole blood and their isolation and characterisation could offer clinicians a routine method with which to diagnose, treat and monitor the progress of various cancers. The main difficulty in successfully analysing CTCs has been the ability to detect low level mutations sufficiently and to create assays that are sensitive enough to provide meaningful data; difficulties which PointMan may be able to effectively overcome. EKF Molecular will design and develop high sensitivity assays which will be utilised by MGH with a view to clinically validating PointMan in the detection of existing and novel mutations, a major step towards the improvement of patient outcomes in the hospital.

EKF Diagnostics Holdings plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

EKF Diagnostics Holdings plc reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported revenue of £16,766,000 compared with £14,887,000 for the same period last year. Operating loss was £1,872,000 compared with operating profit of £659,000 for the same period last year. EBITDA before exceptional items and share-based payment was £2,216,000 compared with £2,124,000 for the same period last year. Loss before income tax was £2,468,000 compared with profit before income tax of £191,000 for the same period last year. Loss attributable to owners of the parent was £2,718,000 or 0.81 pence diluted per share compared with £1,019,000 or 0.36 pence diluted per share for the same period last year. Net cash used in operating activities was £3,317,000 compared with net cash generated by operating activities £1,007,000 for the same period last year. Purchase of property, plant and equipment was £898,000 compared with £293,000 for the same period last year. Purchase of intangibles was £702,000 compared to £630,000 for the same period last year.

EKF Diagnostics Holdings plc Announces Director Appointments

EKF Diagnostics Holdings plc announced the appointment of David Toohey and Doris-Ann Williams MBE to the Board as Non-Executive Directors with immediate effect. David Toohey has over 30 years of experience in international business, the last 20 of which have been in medical devices and the In Vitro Diagnostics industry. He is CEO and founder of Syncrophi Systems Ltd. Doris-Ann Williams has been Chief Executive of the British In Vitro Diagnostics Association since October 2001 and has more than 30 years of experience working in the IVD sector. She has had a variety of experience, initially in R&D and subsequently in commercial roles including international responsibilities. She is on the Editorial board of IVD Technology, sits on a number of steering groups including that of the Technology Strategy Board and is currently on the NHS Implementation Board for Innovation, Health and Wealth. She also works closely with European Diagnostic Manufacturers Association and other global IVD industry associations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.31 EUR +0.018

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies
 

Industry Analysis

LYF

Industry Average

Valuation LYF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 0.9x
Price/Cash Flow 7,865.9x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit www.ekfdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.